Asset Details
Do you wish to reserve the book?
A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis
Do you wish to request the book?
A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis
2024
Overview
Background Chronic inflammation and insulin resistance are highly prevalent in patients on maintenance haemodialysis (MHD) and are strongly associated with protein energy wasting. We conducted a pilot, randomized, placebo‐controlled trial of recombinant human interleukin‐1 receptor antagonist (IL‐1ra) and pioglitazone to explore the safety, feasibility and efficacy for insulin‐mediated protein metabolism in patients undergoing MHD. Methods Twenty‐four patients were randomized to receive IL‐1ra, pioglitazone or placebo for 12 weeks. Changes in serum inflammatory markers and insulin‐mediated protein synthesis, breakdown and net balance in the whole‐body and skeletal muscle compartments were assessed using hyperinsulinaemic–hyperaminoacidemic clamp technique at baseline and Week 12. Results Among 24 patients, median (interquartile range) age was 51 (40, 61), 79% were African American and 21% had diabetes mellitus. All patients initiated on intervention completed the study, and no serious adverse events were observed. There was a statistically significant decrease in serum high‐sensitivity C‐reactive protein in the pioglitazone group compared with placebo, but not in the IL‐1ra group. No significant differences in the changes of whole‐body or skeletal muscle protein synthesis, breakdown and net balance were found between the groups. Conclusions In this pilot study, there were no statistically significant effects of 12 weeks of IL‐1ra or pioglitazone on protein metabolism in patients on MHD. Clinicaltrials.gov registration: NCT02278562.
Publisher
John Wiley & Sons, Inc,Wiley
